McKesson posts strong Q2 FY2027 results, raises FY2027 EPS guidance and completes Precision Medicine Group acquisition
McKesson Corp. reported Q2 FY2027 adjusted earnings of $11.68 per share on revenue of $111.0 billion, an 8% year‑over‑year increase. The company lifted its full‑year FY2027 adjusted EPS outlook to $45.60‑$46.40, up from $44.20‑$45.00. It also closed a $2.25 billion purchase of Precision Medicine Group and announced a $1.4 billion investment for a 49% stake in Option Care Health.
Why it matters
The higher EPS guidance signals stronger profitability expectations for investors, potentially supporting the stock price (the company raised its FY2027 EPS guidance). The Precision Medicine Group deal is expected to contribute $0.10‑$0.20 to FY2027 adjusted EPS, adding incremental earnings (the acquisition details were disclosed in the earnings call).
Key facts
- 1Q2 FY2027 revenue was $111.0 billion, up 8% year‑over‑year. finance.biggo.com
- 2Adjusted EPS for the quarter was $11.68 per share. finance.biggo.com
- 3Full‑year FY2027 adjusted EPS guidance was raised to $45.60‑$46.40. finance.biggo.com
- 4McKesson completed a $2.25 billion acquisition of Precision Medicine Group. finance.biggo.com
- 5The company announced a $1.4 billion investment for a 49% minority interest in Option Care Health. finance.biggo.com
- 6Free cash flow for the quarter was $2.9 billion. finance.biggo.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.